NCT07113314View on ClinicalTrials.gov

Prophylaxis of Febrile Neutropenia With Lactoferrin in Oncohematologic Children Undergoing Induction Chemotherapy

NACompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

March 3, 2018

Study Completion Date

December 15, 2022

Conditions

Febrile Neutropenia (FN)SepsisChemotherapy Treatment

Interventions

DIETARY_SUPPLEMENT

Lactoferrin Bovine

In addition to standard treatment, a gold-soluble formulation of bovine lactoferrin or bLF (Mosiac®) at the standard dose of 200 mg/day, in single administration, from the start of chemo/radiotherapy treatment and throughout the risk period.

Trial Locations (1)

27100

Fondazione IRCCS Policlinico San Matteo Pavia, Pavia

All Listed Sponsors

lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

NCT07113314 - Prophylaxis of Febrile Neutropenia With Lactoferrin in Oncohematologic Children Undergoing Induction Chemotherapy | Biotech Hunter | Biotech Hunter